Furthermore, this study also provides a novel pharmacological target for treating CF patients, and paves the way to therapeutically validate and exploit other complexes that prevent ΔF508-CFTR trafficking to the cell surface (Fig 1). The gene discussed is CFTR; the disease is cystic fibrosis.